Provectus' current speculative bid likely to end badly, Feuerstein writes


Speculative manias tied to Bulletin Board cancer drug stocks usually end badly, and TheStreet's Adam Feuerstein thinks there is nothing to suggest the mania surrounding Provectus Pharmaceuticals (PVCT -6.5%) will be any different.

PVCT shares have soared from $0.80 in December to $6.03 earlier today, doubling in price in the past seven days, amid rumors that FDA officials may sanction an accelerated approval filing of PVCT's long-delayed skin cancer drug PV-10.

While shares surge on speculation that the FDA wants to be more lenient with PV-10's approval pathway, "the more sensible explanation is exactly the opposite... Given the huge advances in melanoma care today, FDA might be telling Provectus that it cannot proceed with the phase III study, as planned," Feuerstein writes.

From other sites
Comments (39)
  • ComputerBlue
    , contributor
    Comments (1367) | Send Message
     
    It is wise for some people to take profits after the run up. It is healthy to have a correction but it doesn't take anything away from the potential.
    23 Jan 2014, 12:08 PM Reply Like
  • jimtenor
    , contributor
    Comment (1) | Send Message
     
    I agree. we still have not heard the results from the FDA meeting, which the agency is supose to give within 30 days!
    23 Jan 2014, 02:44 PM Reply Like
  • SimonSaysShort
    , contributor
    Comments (116) | Send Message
     
    Ahh yes, the good ole 70% correction...
    23 Jan 2014, 03:30 PM Reply Like
  • ComputerBlue
    , contributor
    Comments (1367) | Send Message
     
    Ha, those are my favorite. At that time, it wasn't nearly 70%.
    23 Jan 2014, 03:40 PM Reply Like
  • JimPaul46
    , contributor
    Comments (27) | Send Message
     
    Perhaps the author should spend an hour or 2 looking at what PV10 is and what it does.
    Yep the stock is a rocket ride. However a tumor treatment that has positive results more than 50% of the time and NO side effects is revolutionary. Add in the dermatology prospects and PVCT looks even better. A sell off of big % can happen at any time, but the science is still life changing for cancer patients and their families.
    23 Jan 2014, 12:13 PM Reply Like
  • karmaswimswami
    , contributor
    Comments (125) | Send Message
     
    PVCT investors need to be taking profits and getting out quickly. Their agent is a mere vital dye that acts as a vesicant, a blistering agent, at melanoma lesions. It is as low-tech as low-tech can be, and is neither novel, clever, nor likely to affect melanoma management. Photographs of what it does to patients who receive are genuinely horrifying....scars, blisters, cellulitis. It is fascinating the company never reports long-term follow-up on these patients. My predictions is that they wlll go on to die of widely-metastatic disease caused by the agent. It is a pseudo-immunotherapy for melanoma, and mostly immunotherapies for this disease have failed. It is tell tale that none of the studies of PV-10 have been done in big-name venerable cancer institutions. I don't think it is a scam because I think the company believes its own hype. As Richard Feynman said, in science, the easiest person to fool is always yourself. But do not drink the Rose Bengal Kool-Aid.
    23 Jan 2014, 12:37 PM Reply Like
  • lodnol
    , contributor
    Comments (7) | Send Message
     
    Karmaswimswami, I would like to see the scars, blisters, cellulitis photos of which you speak. Surely if you have seen them you would have no objection to posting them or at least provide a link as to where they may be found. Please. I want to convince myself you are not a short seller. Thank you.
    23 Jan 2014, 02:48 PM Reply Like
  • eastport2007
    , contributor
    Comments (28) | Send Message
     
    Moffit is not a "venerable cancer institution"?
    23 Jan 2014, 02:48 PM Reply Like
  • ComputerBlue
    , contributor
    Comments (1367) | Send Message
     
    http://bit.ly/1mM9XMJ
    23 Jan 2014, 02:49 PM Reply Like
  • lodnol
    , contributor
    Comments (7) | Send Message
     
    I would be interested in seeing the photos of horrifying scars, blisters and cellulitis mentioned in you post. I have a hard time believing that. Surely you would not mind fortifying your post with proof of their existence. Thank you.
    23 Jan 2014, 03:04 PM Reply Like
  • ComputerBlue
    , contributor
    Comments (1367) | Send Message
     
    Click on the link I just posted above.
    23 Jan 2014, 03:08 PM Reply Like
  • lodnol
    , contributor
    Comments (7) | Send Message
     
    Thank you very much for the link. Well as a layperson not astute at all the medical terminology would I be correct in interpreting the report as meaning, the treatment might be ugly but the resulting cure could be wonderful?
    24 Jan 2014, 10:09 AM Reply Like
  • Donindm
    , contributor
    Comments (30) | Send Message
     
    You have to be kidding. These are photos of melanoma tumors being destroyed! PV-10 has no adverse effect on skin except there have been reactions when there is exposure to too much sunlight. If you have melanoma, you should be staying out of the sun!
    24 Jan 2014, 10:45 AM Reply Like
  • evilbarbie
    , contributor
    Comments (63) | Send Message
     
    So we have Adam Feuerstein write a hatchet job on PVCT and the market and shareholders go wild. Not unexpected, the stock is up 1000% since December! I told you to EXPECT wild price fluctuations,

     

    Now let's deal with his hatchet job. RB is obsolete,really. Were going to listen to a blogger who has probably spent a total of three hours researching his piece. He didn't talk to the company, didn't talk to investigators, didn't talk to Moffitt, but the great AF has spoken, BS!

     

    So many KOL's have said the drug is singularly unique not even funny. Moffit who's been in the clinic for almost three years says the drug may "Revolutionize" the treatment for MM!

     

    So AF say's there's NO WAY the FDA will accelerate the approval path? Well the company feels differently and they met 30 days ago to discuss just that. So in the very near future will find out how incredibly wrong AF is. BTW this won't be the first time he's dead wrong. He bill's himself as the Howard Cosel of bloggers with an in your face inflammatory view point.

     

    If you've been considering adding to your PVCT position and it fit's your suitability requirements it's good to do so on pullbacks.

     

    My guess is very shortly the company gives us some news.
    Show message history
    23 Jan 2014, 01:52 PM Reply Like
  • joelkatz
    , contributor
    Comments (570) | Send Message
     
    Yes i'll be adding tomorrow to my position
    23 Jan 2014, 07:59 PM Reply Like
  • Tile
    , contributor
    Comments (116) | Send Message
     
    Adam is entitled to his opinion, but a wise investor should go by what the science says, not by what an angry speculator utters. PV-10 is real science, and the people that are being treated through the compassionate use program (CUP) will testify, and the FDA will listen.
    23 Jan 2014, 02:03 PM Reply Like
  • eastport2007
    , contributor
    Comments (28) | Send Message
     
    The thing is, that Provectus KNOWS what the FDA decision is. Burning shorts is a good thing.
    23 Jan 2014, 02:43 PM Reply Like
  • Jxie
    , contributor
    Comments (2) | Send Message
     
    really?! so that means we just did nothing but only to wait for those Provectus' "valued information"?!
    23 Jan 2014, 04:41 PM Reply Like
  • funnyzguy
    , contributor
    Comments (48) | Send Message
     
    Moffitt Cancer is big-name venerable cancer institution and they did a study on PV-10 and liked it a lot. Here is the link.

     

    http://bit.ly/1dNefk2
    23 Jan 2014, 02:44 PM Reply Like
  • rickcrickc
    , contributor
    Comments (77) | Send Message
     
    Funny- apparently there is a name change going on today & my account listed PVCT as a 7 digit number. Is this getting in the way of "regular" trading? (adding to fear).
    23 Jan 2014, 03:15 PM Reply Like
  • eastport2007
    , contributor
    Comments (28) | Send Message
     
    Name change and change of CUSIP in behalf of registering in Delaware, away from Nevada. To protect from hostile or insufficient bids. IMHO badly executed, not PVCTs fault.
    24 Jan 2014, 09:58 AM Reply Like
  • evilbarbie
    , contributor
    Comments (63) | Send Message
     
    It was a fraud. You could execute a buy at TDAmeritrade just not a sell. I think it is because they loaned our shares out for short interest. If there was a CUSIP error then we would not have been able to buy.
    24 Jan 2014, 11:15 AM Reply Like
  • jdmarr99
    , contributor
    Comments (21) | Send Message
     
    Who thinks AF noticed the problem with name change and timed the post to coincide with many platforms not allowing trading today?
    23 Jan 2014, 03:52 PM Reply Like
  • evilbarbie
    , contributor
    Comments (63) | Send Message
     
    I believe that is stock manipulation and I feel quiet confident there will be an SEC investigation. I for one already have my attorney on it and have filed a formal SEC complaint and I know there are at least 100 more who have stated the same.
    24 Jan 2014, 11:16 AM Reply Like
  • ComputerBlue
    , contributor
    Comments (1367) | Send Message
     
    This was a typical move by those in "the know". Perfect timing and hats off to Adam if he made a bundle for him and his buddies.
    23 Jan 2014, 03:54 PM Reply Like
  • Derrick Lilly
    , contributor
    Comments (366) | Send Message
     
    I have heard from a credible source that spoke directly with PVCT Investor Relations that AF was provided with substantial technical information from the company to help him write his article. It was also said that representatives from the company could not meet his time frame for an interview, and proposed another time, but AF rebuffed and proceeded to write and publish his article without conducting any interviews with PVCT representatives at all, and seemingly ignored the technical info he was provided. Supposedly, the PVCT Board is meeting to discuss a public response. It was said that they normally do not respond to such articles, but are considering it because of the sizable move in the share price and very high trading volume.

     

    For shareholders feeling burned, I would encourage you to email the PVCT IR contacts to show that you want a public response made or at least some acknowledgement to the situation. Contact info here: http://bit.ly/1aNCeh4

     

    We'll see if PVCT comes out with anything, but it appears that AF published his article to support a personal agenda and clearly lacks any journalistic integrity or objectivity.
    23 Jan 2014, 07:40 PM Reply Like
  • eastport2007
    , contributor
    Comments (28) | Send Message
     
    8k with letter is on PVCT site.
    24 Jan 2014, 09:58 AM Reply Like
  • MichaelJ8
    , contributor
    Comments (879) | Send Message
     
    Please view my instablog.
    23 Jan 2014, 09:42 PM Reply Like
  • bradpitt83
    , contributor
    Comments (8) | Send Message
     
    Who is more trustful when you talk about cencer, Adam or Moffitt Cancer Center?
    I doubt that you trust more Adam.
    check this website and make your way right.
    http://bit.ly/1dSywp5
    23 Jan 2014, 10:49 PM Reply Like
  • bradpitt83
    , contributor
    Comments (8) | Send Message
     
    Here is the letter from $PVCT who issued to Adam

     

    Read this and you will see how it goes well,

     

    http://bit.ly/1g7XtPc;pdf=
    24 Jan 2014, 07:30 AM Reply Like
  • gongik
    , contributor
    Comments (5) | Send Message
     
    Feuerstein seems to have deliberately left out some of the most compelling factors that PVCT has to offer with PV-10. He certainly couldn't have been unaware of such basic information. He fails to inform the readers of the successful trial results (ones that entail high response rate and pristine safety), the particularity of PV-10 and its solid patent protection until 2031, and notable recognition of the people/companies in the field (note http://bit.ly/1bmbAsu) Also you have to notice how Feuerstein's article was written in advance to the cancellation of the meeting and it must also be noted that it is most natural reaction on the side of PVCT to cancel a prearranged meeting which most likely has been made at least a few days before as the arrival of the expected official minutes has yet to be delivered. Mum's the word? Yes, that is exactly what PVCT is doing in regards to the official account of the meeting in December.
    24 Jan 2014, 07:40 AM Reply Like
  • evilbarbie
    , contributor
    Comments (63) | Send Message
     
    I am absolutely disgusted by what happened yesterday and have no doubt that there will be an SEC investigation. I never invest what I can't afford to lose but was down many millions as a result yesterday. I see this as a one or two day setback. You didn't lose money if you didn't sell. I am most sad and it brings tears to my eyes getting messages from investors who say they lost half of their retirement and worse because of this article and the people on message boards suggesting this is a pump and dump. This is a very, very sad situation for many and they should be in our thoughts. Adam I have one thing to say to you, Karma is a b#$@$!!!!!
    24 Jan 2014, 11:22 AM Reply Like
  • lodnol
    , contributor
    Comments (7) | Send Message
     
    I bought another big chunk this morning. Some at 2.66 and some at 2.90. I believe there was malice in Fuersteins rant and I believe he profited from the drop.
    24 Jan 2014, 12:31 PM Reply Like
  • bradpitt83
    , contributor
    Comments (8) | Send Message
     
    I doubt that anyone with a sane mind would trust an individual with a political science background and a habit of reckless bashing of stocks that he dislikes without suggesting any solid facts!

     

    http://bit.ly/1dSywp5
    24 Jan 2014, 12:27 PM Reply Like
  • bradpitt83
    , contributor
    Comments (8) | Send Message
     
    This article explains why Provectus' drug is a paradigm shift in the treatment of cancer and why Adam Feuerstein's article was totally WRONG. The fundamental hasn't changed one bit. Just as Adam's speculative bashing cannot reduce the proven efficacy of PV-10 even to the slightest degree.

     

    this is the article

     

    http://bit.ly/1bmbtgB
    24 Jan 2014, 12:28 PM Reply Like
  • evilbarbie
    , contributor
    Comments (63) | Send Message
     
    ADAM YOU ARE SO WRONG!!! CHECK OUT THE PR FROM $PVCT!!!! http://bit.ly/1fifUMk

     

    Get a life and start being an actual journalist or author or whatever it is you think you are and write something factual.
    24 Jan 2014, 12:33 PM Reply Like
  • scheven_architect
    , contributor
    Comments (2) | Send Message
     
    Bought 2700$ of shares yesterday inb4 the disgusting article of Adam Fuckerstein. Now worth 1000$... All because one POS who enriches himself and his entourage spreading lies. Enjoy the Ace of Spades on your yacht, paid with your scam...
    24 Jan 2014, 04:56 PM Reply Like
  • evilbarbie
    , contributor
    Comments (63) | Send Message
     
    Everyone check this website out please. All the info you need to know about Adam Feuerstein. http://bit.ly/zcz1QE
    25 Jan 2014, 09:23 AM Reply Like
  • Ron Alwin
    , contributor
    Comments (74) | Send Message
     
    How in the world does AF get any credibility or the street.com for that matter. It is easy to bash bio on fundability as they have with my pick $CYTR often. however the stories with these stocks is not how much they earn..as most don't but what their future brings. I haven't followed PVCT but have experienced the faulty reporting on CYTR from them. they have a sell-sell-sell and keep posting it on CYTR...funny thing though if you followed them you would of lost a serious amount of dollars. Someone needs to expose them and the tactics they use to short for a very few people gains while they reek havoc on the rest of us.
    26 Jan 2014, 03:13 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs